Literature DB >> 3019564

Demonstration of virus-specific transcriptional activator(s) in cells infected with HTLV-III by an in vitro cell-free system.

T Okamoto, F Wong-Staal.   

Abstract

Human T cell lymphotropic viruses (HTLV's) differ from most other retroviruses based on the presence of trans-regulatory genes for virus expression. In this study, using an in vitro cell-free transcription system, we demonstrate that nuclear extracts obtained from cells infected with HTLV-III (human immunodeficiency virus, HIV) contain a factor(s) that stimulates transcription specifically from the HTLV-III promoter. Present studies indicate that this activation is mainly involved in the initiation of transcription from the HTLV-III promoter.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3019564     DOI: 10.1016/0092-8674(86)90363-6

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  52 in total

1.  Activity of synthetic tat peptides in human immunodeficiency virus type 1 long terminal repeat-promoted transcription in a cell-free system.

Authors:  J Jeyapaul; M R Reddy; S A Khan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

2.  Role of SP1-binding domains in in vivo transcriptional regulation of the human immunodeficiency virus type 1 long terminal repeat.

Authors:  D Harrich; J Garcia; F Wu; R Mitsuyasu; J Gonazalez; R Gaynor
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

3.  Mutational analysis of the trans-activation-responsive region of the human immunodeficiency virus type I long terminal repeat.

Authors:  J Hauber; B R Cullen
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

4.  trans-acting factors interact with a cyclic AMP response element to modulate expression of the human gonadotropin alpha gene.

Authors:  J L Jameson; P J Deutsch; G D Gallagher; R C Jaffe; J F Habener
Journal:  Mol Cell Biol       Date:  1987-09       Impact factor: 4.272

5.  Localization of sequences responsible for trans-activation of the equine infectious anemia virus long terminal repeat.

Authors:  L Sherman; A Gazit; A Yaniv; T Kawakami; J E Dahlberg; S R Tronick
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

6.  Transactivation of heterologous promoters by HIV-1 tat.

Authors:  P Han; R Brown; J Barsoum
Journal:  Nucleic Acids Res       Date:  1991-12       Impact factor: 16.971

7.  Inhibition of human immunodeficiency virus type 1 replication in latently infected cells by a novel IkappaB kinase inhibitor.

Authors:  Ann Florence B Victoriano; Kaori Asamitsu; Yurina Hibi; Kenichi Imai; Nina G Barzaga; Takashi Okamoto
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

8.  Identification of lentivirus tat functional domains through generation of equine infectious anemia virus/human immunodeficiency virus type 1 tat gene chimeras.

Authors:  R Carroll; L Martarano; D Derse
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

9.  Isolation of a cellular protein that binds to the human immunodeficiency virus Tat protein and can potentiate transactivation of the viral promoter.

Authors:  K Desai; P M Loewenstein; M Green
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

10.  Analysis of regulatory elements of the equine infectious anemia virus and caprine arthritis-encephalitis virus long terminal repeats.

Authors:  L Sherman; A Yaniv; H Lichtman-Pleban; S R Tronick; A Gazit
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.